Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination-Reference-Cited by-同舟云学术

Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination

Published:2023-06-22 Issue:3 Volume:8 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Castro Eliana F.¹²,Acosta Julián³⁴,Moriena Lucía⁵,Rios Medrano Mayra¹,Tejerina Cibello Malena⁶,Codino Eduardo⁴⁵,Taborda Miguel Ángel⁴,Álvarez Diego E.¹⁶^ORCID,Cavatorta Ana Laura³⁴⁵

Affiliation:

1. Instituto de Investigaciones Biotecnológicas (IIBIO), Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

2. Instituto de Virología e Innovaciones Tecnológicas (IVIT), Centro de Investigaciones en Ciencias Veterinarias y Agronómicas (CICVyA), Instituto Nacional de Tecnología Agropecuaria (INTA, CONICET), Buenos Aires, Argentina

3. Instituto de Biología Molecular y Celular de Rosario-CONICET, Santa Fe, Argentina

4. Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Santa Fe, Argentina

5. Centro de Tecnología en Salud Pública (CTSP), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Santa Fe, Argentina

6. Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, Buenos Aires, Argentina

Abstract

Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people.

Funder

Ministerio de Salud Publica de Santa Fe

Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/msphere.00662-22

Reference36 articles.

1. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

2. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

3. Russian Direct Investment Fund. 2003. About Sputnik V. https://sputnikvaccine.com/about-vaccine/.

4. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

5. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination